Results of the phase 2 diagnostic investigator-initiated trial of 64Cu SAR-Bombesin in prostate cancer (BOP) have shown the novel theranostic radiopharmaceutical can detect lesions in men with biochemically recurrent (BCR) prostate cancer that are either negative or equivocal on prostate-specific membrane antigen positron emission tomography (PSMA PET). ...
RLT-PSMA
Advertisement
Latest News
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
The National Comprehensive Cancer Network now includes POSLUMA in its clinical practice guidelines for prostate cancer.
![PYTHON Trial Shows Higher Detection Rate of [18F]DCFPyL Compared With [18F]Fluoromethylcholine](https://mumcdnstorage.blob.core.windows.net/guonc/2022/10/PETCT.png)
[18F]DCFPyL impacted patient management in 44% of patients vs 29% of patients who received [18F]fluoromethylcholine.
![[177Lu]Lu-PSMA-617 Plus Standard of Care Versus Standard of Care Alone for Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2022/12/Metastatic-prostate-cancer.png)
The VISION trial assigned patients to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Advertisement
